Akari Therapeutics PLC (AKTX)
2.429
-0.35
(-12.61%)
USD |
NASDAQ |
Nov 04, 16:00
2.42
-0.01
(-0.39%)
After-Hours: 20:00
Akari Therapeutics Enterprise Value: 25.86M for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 25.86M |
| November 01, 2024 | 30.05M |
| October 31, 2024 | 25.51M |
| October 30, 2024 | 25.63M |
| October 29, 2024 | 26.71M |
| October 28, 2024 | 25.51M |
| October 25, 2024 | 25.09M |
| October 24, 2024 | 23.96M |
| October 23, 2024 | 23.24M |
| October 22, 2024 | 22.32M |
| October 21, 2024 | 22.64M |
| October 18, 2024 | 23.60M |
| October 17, 2024 | 23.24M |
| October 16, 2024 | 26.95M |
| October 15, 2024 | 27.32M |
| October 14, 2024 | 28.56M |
| October 11, 2024 | 29.10M |
| October 10, 2024 | 28.38M |
| October 09, 2024 | 32.09M |
| October 08, 2024 | 33.40M |
| October 07, 2024 | 33.10M |
| October 04, 2024 | 32.75M |
| October 03, 2024 | 32.68M |
| October 02, 2024 | 32.44M |
| October 01, 2024 | 32.68M |
| Date | Value |
|---|---|
| September 30, 2024 | 32.09M |
| September 27, 2024 | 31.97M |
| September 26, 2024 | 33.28M |
| September 25, 2024 | 34.60M |
| September 24, 2024 | 32.44M |
| September 23, 2024 | 35.07M |
| September 20, 2024 | 35.31M |
| September 19, 2024 | 34.60M |
| September 18, 2024 | 34.36M |
| September 17, 2024 | 36.51M |
| September 16, 2024 | 35.91M |
| September 13, 2024 | 35.73M |
| September 12, 2024 | 36.27M |
| September 11, 2024 | 38.65M |
| September 10, 2024 | 37.64M |
| September 09, 2024 | 36.27M |
| September 06, 2024 | 36.51M |
| September 05, 2024 | 35.65M |
| September 04, 2024 | 40.57M |
| September 03, 2024 | 40.75M |
| August 30, 2024 | 42.60M |
| August 29, 2024 | 42.37M |
| August 28, 2024 | 42.25M |
| August 27, 2024 | 41.65M |
| August 26, 2024 | 42.25M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.016M
Minimum
Mar 30 2023
135.22M
Maximum
Feb 19 2021
41.70M
Average
41.09M
Median
Enterprise Value Benchmarks
| DBV Technologies SA | 9.250M |
| Cellectis SA | -52.07M |
| Adaptimmune Therapeutics PLC | 18.55M |
| Biodexa Pharmaceuticals PLC | -2.612M |
| NuCana PLC | -11.24M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.558M |
| Total Expenses (Quarterly) | 5.555M |
| EPS Diluted (Quarterly) | -0.8025 |
| Earnings Yield | -88.77% |